Summit Therapeutics Inc's next confirmed earnings release is scheduled for March 18, 2027.
| Earnings Date | 3/18/2027 |
As of September 30, 2026, Summit Therapeutics Inc has 799.73M shares outstanding.
| Shares Outstanding | 799.73M |
As of September 30, 2026, Summit Therapeutics Inc maintains a current ratio of 5.99, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.99 |
| Quick Ratio | 5.71 |
| Debt / Equity | 3.54 |
| Debt / EBITDA | -0.02 |
Over the twelve months ended September 30, 2026, Summit Therapeutics Inc posted a negative return on equity (ROE) of -220.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -174.46, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 265.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -220.01 |
| Return on Assets (ROA) | -174.46 |
| Employee Count | 265.00 |
As of the close on October 27, 2026, Summit Therapeutics Inc's stock has declined approximately 19.44% over the past 52 weeks.
| 52-Week Price Change | -19.44% |
Over the twelve months ended September 30, 2026, Summit Therapeutics Inc generated - - in revenue and converted that into -15.04B in net income, yielding earnings per share of -19.29. EBITDA reached -15.44B, while operating income came in at -15.44B.
| Operating Income | -15.44B |
| Pretax Income | -15.03B |
| Net Income | -15.04B |
| EBITDA | -15.44B |
| EBIT | -15.44B |
| Earnings Per Share (EPS) | -19.29 |
As of September 30, 2026, Summit Therapeutics Inc holds 11.37B in cash and equivalents against 360.82M in total debt, resulting in a net debt position of -2.72B. Total book value stands at 10.20B, with working capital of 9.94B providing operational flexibility.
| Cash & Cash Equivalents | 11.37B |
| Total Debt | 360.82M |
| Net Debt | -2.72B |
| Equity (Book Value) | 10.20B |
| Book Value Per Share | 12.75 |
| Working Capital | 9.94B |
Summit Therapeutics Inc produced -9.48B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -30.95M in capital expenditures, free cash flow totaled -9.51B - equivalent to -12.20 per share.
| Operating Cash Flow | -9.48B |
| Capital Expenditures | -30.95M |
| Free Cash Flow | -9.51B |
| FCF Per Share | -12.20 |